Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
ASTRAZENECA'S combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday.
The so-called Mystic study was the most anticipated...